[Use of mindronate in cardiac insufficiency in patients with ischemic heart disease].
A clinical trial of Soviet drug mildronate has proved its antiarrhythmic action, the ability to prevent ventricular extrasystoles, to reduce asthenia, to enhance physical performance and adaptive reactions. The heart rate decrease appeared insignificant. Intravenous administration of the drug improves myocardial contractility. Mildronate is well tolerated. No side effects were registered.
L I
LI
Ol'binskaia
G M
GM
Golokolenova
D000328:Adult; D000368:Aged; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000150:complications* / Q000503:physiopathology; D005260:Female; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008297:Male; D008763:Methylhydrazines / Q000627:therapeutic use*; D008875:Middle Aged; D014665:Vasodilator Agents
D008763:Methylhydrazines; D014665:Vasodilator Agents; C050147:3-(2,2,2-trimethylhydrazine)propionate
Primenenie mindronata pri serdechnoĭ nedostatochnosti u bol'nykh ishemicheskoĭ bolezn'iu serdtsa.